Analyst: New Bavarian Nordic initiatives reflect soaring monkeypox vaccine demand

The Danish vaccine maker is showing signs of trying to meet rising demand for the monkeypox vaccine, and this can only be a good thing, according to a Sydbank analyst.

Photo: Bavarian Nordic / PR

The monkeypox outbreak has put pressure on Bavarian Nordic as the only company in the world with a vaccine against the disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs